{"organizations": [], "uuid": "5051731eda454367d5b30752cace7833b3a532c9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180301.html", "section_title": "Archive News &amp; Video for Thursday, 01 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-argenx-fy-total-operating-income-r/brief-argenx-fy-total-operating-income-rises-to-41-3-million-euros-idUSW8N1KI005", "country": "US", "domain_rank": 408, "title": "Argenx FY Total Operating Income Rises To 41.3 Million Euros", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.212, "site_type": "news", "published": "2018-03-01T14:41:00.000+02:00", "replies_count": 0, "uuid": "5051731eda454367d5b30752cace7833b3a532c9"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-argenx-fy-total-operating-income-r/brief-argenx-fy-total-operating-income-rises-to-41-3-million-euros-idUSW8N1KI005", "ord_in_thread": 0, "title": "Argenx FY Total Operating Income Rises To 41.3 Million Euros", "locations": [], "entities": {"persons": [], "locations": [{"name": "pemphigus", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "aml", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 1 (Reuters) - Argenx Nv:\n* FY REVENUE EUR 36.4‍​ MILLION VERSUS EUR 14.7 MILLION YEAR AGO\n* FY TOTAL OPERATING INCOME EUR 41.3 MILLION VERSUS EUR 17.2 MILLION YEAR AGO\n* FY TOTAL COMPREHENSIVE LOSS EUR ‍​28.1 MILLION VERSUS LOSS OF EUR 21.4 MILLION YEAR AGO\n* CASH, CASH EQUIVALENTS AND CURRENT FINANCIAL ASSETS EUR 359.8 MILLION AT DEC. 31\n* IN 2018 PLANS TO REPORT FULL DATA FROM PHASE 2 PROOF-OF-CONCEPT TRIAL FOR ARGX-113 IN GENERALIZED MG\n* FY OPERATING LOSS EUR 22.9 MILLION VERSUS LOSS EUR 21.4 MILLION YEAR AGO\n* IN 2018 PLANS TO REPORT TOPLINE DATA OF PHASE 2 PROOF-OF-CONCEPT TRIAL FOR ARGX-113 IN ITP\n* IN H2 PLANS TO REPORT INTERIM DATA OF PHASE 2 PROOF-OF-CONCEPT TRIAL FOR ARGX-113 IN PEMPHIGUS VULGARIS\n* BEFORE END-2018 PLANS TO PROGRESS ARGX-113 INTO PHASE 3 CLINICAL DEVELOPMENT IN GENERALIZED MG\n* IN Q2 PLANS TO REPORT FULL DATA OF PHASE 1 HEALTHY VOLUNTEER TRIAL WITH SUBCUTANEOUS FORMULATION OF ARGX-113\n* IN H2 PLANS TO PROVIDE AN UPDATE ON PHASE 1/2 CLINICAL TRIAL IN AML\n* BY END-YEAR PLANS TO REPORT FULL DATA OF AML PHASE 1/2 AND CTCL PHASE 2 CLINICAL TRIALS OF ARGX-110\n* BEFORE END-2018 PLANS TO LAUNCH PHASE 2 PROOF-OF-CONCEPT TRIAL FOR ARGX-110 IN AML\n* BEFORE END-2018 PLANS TO REPORT FULL DATA OF PHASE 2 PROOF-OF-CONCEPT TRIAL FOR ARGX-113 IN ITP Source text: bit.ly/2t8eDce (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html", "http://bit.ly/2t8eDce"], "published": "2018-03-01T14:41:00.000+02:00", "crawled": "2018-03-02T19:40:15.059+02:00", "highlightTitle": ""}